BioCryst Gets FDA Approval To Treat Rare Childhood Swelling Disorder With Oral Drug

BioCryst secures FDA approval for Orladeyo oral pellets, expanding preventive HAE therapy to children ages 2 to under 12.

BioCryst wins FDA approval for Orladeyo oral pellets

BioCryst Pharma (BCRX) announced on Friday that the U.S. Food and Drug Administration (FDA) approved an oral pellet ...

FDA approves BioCryst's oral pellet formulation of rare disease drug for young children

The U.S. Food and Drug Administration has approved an oral pellet formulation of BioCryst Pharmaceuticals' drug to prevent hereditary angioedema attacks in children aged 2 to under 12, the company ...

How to spot suspicious health supplements and avoid getting scammed

Snopes readers regularly ask whether supplement brands like Neurocept and Burn Peak are legit. Here's how you can tell yourself.
IEEE

Capsule Networks With Residual Pose Routing

Abstract: Capsule networks (CapsNets) have been known difficult to develop a deeper architecture, which is desirable for high performance in the deep learning era, due to the complex capsule routing ...